צמיחת רווחי EPS רבעונית SciSparc Ltd (SPRC)
SciSparc Ltd is a reputable developer in neurology that synthesizes classical chemistry with cannabinoids. The company is currently focusing on its own tests of psychoactive compounds, limiting partnerships strictly to scientific alliances. Specialists are creating safe formulas to combat dementia and Tourette syndrome. The quarterly EPS dynamics reflect the financial condition, where 0.00 is the current value of the indicator.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_SPRC_-_SciSparc-Ltd_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "צמיחת רווחי EPS רבעונית scisparc.com (SPRC): לתקופה 21.02.2024 - 14.11.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור SciSparc Ltd (SPRC)
The market evaluates the potential of SciSparc Ltd (SPRC) through the lens of future revenues from innovative autism therapy, which is reflected in the quarterly EPS dynamics profile. This indicator measures the percentage change in net income per share, allowing investors to distinguish random price spikes from the sustainable capitalization growth typical of biotech assets with long-term patent protection.
